Market Trends of Europe Regenerative Medicines Industry
Cardiovascular Application is Expected to Cover a Large Share of the Market Over the Forecast Period
Cardiac stem-cell therapy has great potential to prompt myocardial regeneration in patients with ischemic heart disease. The selection of the most suitable cell type is pivotal for its successful application. Various cell types, including crude bone marrow mononuclear cells, skeletal myoblast, and hematopoietic and endothelial progenitors, have already advanced into the clinical arena, based on promising results from different experimental and preclinical studies. Different next-generation cell types are also under investigation, for the treatment of diseased myocardium.
As per the fact sheet published in August 2022, by the British Heart Foundation, around 7.6 million people are living with heart and circulatory diseases in the United Kingdom. Around 4 million males and 3.6 million females are living with heart and circulatory diseases in the United Kingdom. As per the same source, there are 2.3 million people in the United Kingdom living with coronary heart disease (CHD) - around 1.5 million men and 830,000 women. As the incidence of CVD increases in Europe, the demand for cardiac regenerative techniques in applications like cardiac stem (CSCs) and progenitor cells (CPCs) is also expected to increase. This is expected to help the market to grow in the future.
Thus, the segment is anticipated to witness significant growth over the forecast period due to the abovementioned factors.
France is Expected to Dominate the Europe Regenerative Medicines Market
France is expected to dominate the market owing to factors such as the increasing adoption of innovative therapies in the treatment of chronic diseases that will drive industry expansion. The rising incidence of several chronic diseases in the country will further boost product demand. Moreover, high investment in the development of healthcare infrastructure and high spending capacity on healthcare will propel market growth. Moreover, government funding and reimbursement policies in facilities along with new product launches in the region will impel the market size.
In September 2021, Christian Jorgensen, Rosanna Feirrera Lopez, Loïc Le Coz, and Marion Bertrand-Marchand M.D., formed a series of Circles aimed at standardizing orthobiologic treatments through real-world evidence. Unlike a traditional study, all clinicians will be free to use their professional judgment in the use of devices, clinical protocol, and patient selection, but by aggregating and benchmarking their long-term patient outcomes, will begin answering key clinical questions surrounding various regenerative medicine products. This collaborative, titled 'Regenerative Medicine Services of France' planned to enroll its first patient in mid-September.
Moreover, in September 2022, KCAS expanded its transatlantic presence with the acquisition of France-based active biomarkers. Moreover in June 2021, Yposkesi built its second commercial facility for cell and gene therapy manufacturing at its campus in Corbeil-Essonnes, France. Project SKY is intended to be a new global resource for drug developers of biologics. These Developments in the region are expceted to boost the growth of the market in the region over the forecast period.
Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the France Region.
